Revenue Performance - For the six months ended June 30, 2024, the company's total revenue was approximately RMB 2,363.8 million, a decrease of 3.0% compared to RMB 2,438.0 million for the same period in 2023[3]. - Revenue from the specialty pharmacy business was approximately RMB 2,066.8 million, down 4.3% from RMB 2,158.8 million year-on-year, while revenue from the drug distribution business plummeted by 69.6% to approximately RMB 83.9 million, accounting for only 3.5% of total revenue[2][3]. - The revenue for the special drug pharmacy business decreased by approximately 4.3% to RMB 2,066.76 million for the six months ended June 30, 2024, compared to RMB 2,158.76 million for the same period in 2023[14]. - The revenue for the doctor research assistance business increased by approximately 9.9% to RMB 187.37 million for the six months ended June 30, 2024, compared to RMB 170.51 million for the same period in 2023[14]. - The revenue for the health insurance services business increased by approximately 0.9% to RMB 109.65 million for the six months ended June 30, 2024, compared to RMB 108.69 million for the same period in 2023[14]. - The revenue breakdown includes RMB 2,066,761 from the specialty pharmacy business, RMB 187,371 from the physician research assistance business, and RMB 109,648 from the health insurance services business[46]. Profitability and Losses - Adjusted losses narrowed by approximately 47.4% to about RMB 29.7 million, primarily due to organic growth and efficiency improvements across business lines[2][3]. - The gross profit for the reporting period was approximately RMB 228.9 million, reflecting a 5.0% increase compared to RMB 218.1 million in the previous year[3]. - The total gross profit increased by approximately 5.0% to RMB 228.93 million for the six months ended June 30, 2024, compared to RMB 218.09 million for the same period in 2023[16]. - The company reported a loss of RMB 74.65 million, compared to a loss of RMB 87.31 million for the same period in 2023, indicating a 14.9% improvement in performance[22]. - The non-IFRS loss for the same period was RMB 28.79 million, a decrease from RMB 33.19 million in 2023, reflecting a 13.5% reduction[22]. - The group reported a loss before tax of RMB 75,159 for the six months ended June 30, 2024, compared to a loss of RMB 86,698 for the same period in 2023, indicating an improvement[45][48]. - The company reported a loss attributable to ordinary equity holders of RMB 78,202,000 for the six months ended June 30, 2024, compared to a loss of RMB 92,321,000 for the same period in 2023, representing a 15.3% improvement[58]. Operational Efficiency - The company continues to focus on organic growth and operational efficiency while investing in digitalization and collaborative development strategies[2][5]. - The company has streamlined its drug distribution business to concentrate on its core operations, enhancing operational capital efficiency[2]. - Sales and marketing expenses decreased by approximately 9.4% to about RMB 137.82 million due to efficiency improvements related to the special drug pharmacy and health insurance services[17]. - Total operating expenses for the six months ended June 30, 2024, were RMB 317,115, compared to RMB 352,078 for the same period in 2023, reflecting a decrease of 9.9%[44][47]. Financial Position - Cash and specific financial assets decreased by 10.3% to RMB 1,338.7 million compared to RMB 1,492.3 million in the previous year[3]. - As of June 30, 2024, the company's current assets net value was approximately RMB 1,120 million, with a debt-to-asset ratio of 48.2%, up from 42.1% as of December 31, 2023[24]. - The net cash outflow from operating activities for the six months ended June 30, 2024, was approximately RMB 12.8 million[23]. - The company held cash and cash equivalents of RMB 279.38 million as of June 30, 2024, with total financial assets amounting to approximately RMB 1,338.73 million[25]. - The company reported capital expenditures of RMB 8.81 million for the six months ended June 30, 2024, compared to RMB 3.62 million in the same period of 2023, representing a 143.5% increase[28]. - The company's total liabilities increased to RMB 1,404,724 thousand as of June 30, 2024, compared to RMB 1,183,889 thousand at the end of 2023[39]. - The company's equity attributable to owners of the parent decreased to RMB 1,496,483 thousand as of June 30, 2024, from RMB 1,618,859 thousand at the end of 2023[39]. Employee and Governance - The company employed 3,250 employees as of June 30, 2024, primarily based in China[31]. - The company is committed to maintaining high standards of corporate governance and has adopted the corporate governance code as per the listing rules[64]. - The independent auditor, Ernst & Young, reviewed the interim financial information for the six months ending June 30, 2024, in accordance with the relevant standards[67]. Shareholder Information - The company did not declare or pay any dividends during the reporting period, consistent with the previous period[56]. - The company has not declared an interim dividend for the six months ended June 30, 2024[35]. - The weighted average number of ordinary shares in issue for the six months ended June 30, 2024, was 644,308,040, slightly down from 645,494,859 for the same period in 2023[58]. - The company repurchased and cancelled 1,525,200 ordinary shares during 2023, costing RMB 10,117,000[62]. - The company issued 1,190,600 ordinary shares due to the exercise of share options, generating proceeds of RMB 588,000 during the six months ended June 30, 2024[63].
思派健康(00314) - 2024 - 中期业绩